Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression

• Sharmilee Gnanapavan ,

  * E-mail: s.gnanapavan@ucl.ac.uk

  Affiliation Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom

  ⨯
• Donna Grant,

  Affiliation Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom

  ⨯
• Steve Morant,

  Affiliation Independent Statistician, Haddenham, Bucks, United Kingdom

  ⨯
• Julian Furby,

  Affiliation Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom

  ⨯
• Tom Hayton,

  Affiliation Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom

  ⨯
• Charlotte E. Teunissen,

  Affiliation Department of Clinical Chemistry, VU University Medical Center Amsterdam, Amsterdam, The Netherlands

  ⨯
• Valerio Leoni,

  Affiliation Laboratory of Clinical Pathology and Medical Genetics, Foundation IRCCS Neurology Institute “Carlo Besta”, Milano, Italy

  ⨯
• Monica Marta,

  Affiliation Blizzard Institute, Queen Mary University London, London, United Kingdom

  ⨯
• Robert Brenner,

  Affiliation Department of Clinical Neuroscience, Royal Free Hospital, London, United Kingdom

  ⨯
• Jacqueline Palace,

  Affiliation University Department of Clinical Neurology, Radcliffe Infirmary, Oxford, United Kingdom

  ⨯
• David H. Miller,

  Affiliation Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom

  ⨯
• Raj Kapoor,

  Affiliation Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom

  ⨯
• Gavin Giovannoni

  Affiliation Blizzard Institute, Queen Mary University London, London, United Kingdom

  ⨯